Integra LifeSciences IART Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Integra LifeSciences's additional paid-in capital?
- Integra LifeSciences (IART) reported additional paid-in capital of $1.34B in Q1 2026.
- How has Integra LifeSciences's additional paid-in capital changed year-over-year?
- Integra LifeSciences's additional paid-in capital increased by 1.3% year-over-year, from $1.32B to $1.34B.
- What is the long-term trend for Integra LifeSciences's additional paid-in capital?
- Over 5 years (2020 to 2025), Integra LifeSciences's additional paid-in capital has grown at a 0.7% compound annual growth rate (CAGR), from $1.29B to $1.34B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.